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ABSTRACT
Estrogen therapy has been taken as a settled approach for both prevention and treatment of 
osteoporosis, especially in post-menopausal women as well as for the treatment of symptoms 
associated with menopause. Recent studies suggest that nuclear factor kappa-B ligand/receptor 
activator of nuclear factor kappa-B/osteoprotegerin system plays a significant role in osteoclastic 
activity regulation, with receptor activator of nuclear factor kappa-B ligand signaling in 
the presence of macrophage colony stimulating factor leading to increase in osteoclastic 
differentiation and functioning while osteoprotegerin neutralizing receptor activator of nuclear 
factor kappa-B ligand. Estrogen acts by increasing osteoprotegerin levels, and decreasing 
macrophage colony stimulating factor and receptor activator of nuclear factor kappa-B, thereby 
reducing bone resorption. Furthermore, estrogen is also known to be causing increased calcium 
absorption. The use of estrogen therapy in patients of osteoporosis is also considered to be 
highly cost effective. On the negative side, studies have shown that oral estrogen therapy can 
lead to complications like cholelithiasis, thrombophlebitis and pulmonary embolism, the most 
detrimental being endometrial cancer. But studies have shown that it can be virtually eliminated 
with the addition of progesterone in the cyclic combined regimen. Majority of beneficial effects 
occur with long term use of estrogen therapy, but the compliance by most of women appears to 
be poor. Additional studies should therefore be conducted to evaluate in detail the causes of non-
compliance and strategies to improve compliance. The benefit of quality of life improvement 
with estrogen therapy should be taken into account and further evaluated via studies.
MAIN BODY
Osteoporosis is defined as a skeletal disruption with de-
creased bone mineral density (BMD), ideally recorded by 
dual-energy X-ray absorptiometry (DXA) as 2.5 standard 
deviation (SD) below the mean BMD reference (1). Due 
to its prevalence globally, osteoporosis is considered as a 
serious public health concern and currently it is estimated 
that greater than 200 million people world-wide bear the dis-
ease (2). However, the prevalence of osteoporosis is differed 
by race, gender, ethnicity and it rises with age (3). It can be 
further branched out as primary or secondary osteoporosis. 
Primary osteoporosis can occur in both men and women at 
any age, though particularly affecting postmenopausal wom-
en, elderly men and in children with conditions such as Ju-
venile Idiopathic Osteoporosis and Osteogenesis  Imperfecta 
(1, 4). Secondary osteoporosis can be due to numerous caus-
es including drug therapy (glucocorticoids), endocrine dis-
orders, hematological diseases, gastrointestinal disorders, 
nutritional insufficiencies, alcohol intake and organ trans-
plant (1, 4, 5). As a result of compromised bone strength, 
patients of osteoporosis are prone to fractures, and the risk 
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grows with age (1). Studies have shown increased incidence 
of vertebral, hip, and wrist fractures in these patients (6), 
consequently affecting the quality of life (1). Furthermore, 
patients with osteoporosis are reported to have psychologi-
cal impacts, including depression and anxiety (1, 7). Overall 
osteoporosis with its widespread results not only affects the 
individual, but also the family and ultimately the communi-
ty. Early diagnosis of bone loss and fracture risk are import-
ant because of the availability of therapies that can prevent 
or reverse the progression of osteoporosis (1).
Diverse treatment options have been considered for oste-
oporosis and numerous studies have shown evidence based 
conclusion on various modalities. The modalities commonly 
used for the treatment of osteoporosis include exercise, cal-
cium, vitamin D, bisphosphonates (4), selective estrogen re-
ceptor modulators (SERMS) and estrogen replacement ther-
apy (1, 8, 9). Estrogen therapy has been taken as a settled 
approach for both prevention and treatment of osteoporosis, 
especially in post-menopausal women (1, 8-10) as well as for 
the treatment of symptoms associated with menopause (9, 11). 
The mechanism of action of estrogen is unknown, consisting 
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of several theories. Early studies on estrogen have shown that 
it is known to act on pro inflammatory factors (that increase 
bone resorption) by down regulating them. Recent studies 
suggest that nuclear factor kappa-B ligand (NF-KappaB Li-
gand)/receptor activator of nuclear factor kappa-B (RANK)/
osteoprotegerin (OPG) system plays a significant role in os-
teoclastic activity regulation, with RANKL signaling in the 
presence of Macrophage Colony Stimulating Factor (MCSF) 
leading to increase in osteoclastic differentiation and func-
tioning while OPG neutralizing receptor activator of nuclear 
factor kappa-B ligand (RANKL). Estrogen acts by increasing 
OPG levels, and decreasing MCSF and RANK, thereby re-
ducing bone resorption (9, 12). Furthermore, estrogen is also 
known to be affecting calcium regulation at gut and kidney, 
leading to increased calcium absorption (9). Studies have 
shown that estrogen causes a decrease in the levels of uri-
nary calcium, hydroxyprolene, causes calcitonin stimulation 
and affects parathyroid hormone (PTH) (10). However, more 
data is required to evaluate the more definitive mechanism of 
estrogen action.
The route of administration of estrogen can be oral as 
well as transdermal, both associated with increased bone 
density (10, 12). Estrogen replacement therapy as different 
oral regimens, transdermal patches as well as suppositories 
have a key role in the prevention of osteoporosis by slowing 
down the bone loss phase. Studies have shown that those 
patients who had bilateral oophorectomy, if were started on 
estrogen replacement therapy within 6 weeks, showed total 
halt of bone loss. Those who were given the therapy a few 
years after oophorectomy also showed signs of improve-
ment, though the effects were less striking as compared to 
early treatment (starting within six weeks of the onset of 
menopause) (10, 13). Along with the rise in bone density, 
estrogen via its effect on collagen also has favorable effects 
on intervertebral disc as well as bone matrix. This effect 
is superior to bisphosphonates as they don’t carry this ef-
fect (14). In addition to a decrease in bone loss and increase 
in bone density, there is strong evidence which shows that 
estrogen therapy decreases the overall incidence of osteo-
porosis-related fractures (10, 15). The results of epidemio-
logical and observational studies are now supported by clin-
ical randomized trials which shows that oral combinations 
of HRT is associated with a 30% reduction in vertebral and 
non-vertebral fractures (15, 16). A meta-analysis also re-
vealed 27% incidence of non-vertebral fractures in patients 
undergoing hormone replacement therapy (HRT) therapy 
(15, 17). Women’s health initiative (WHI) randomized con-
trol trial (15, 18) revealed that hip and clinical vertebral frac-
ture were reduced by 34% and total osteoporotic fractures by 
24%. Another study supports that estrogen is very effective 
in the prevention of wrist and hip fractures in older women 
(19). Studies have also shown the importance of estrogen’s 
role in the development and maintenance of male skeleton 
as well. Hence, estrogen therapy can be considered as a ben-
eficial treatment option for osteoporosis in men (20). Added 
 advantages of estrogen replacement therapy includes reduc-
tion of vasomotor symptoms, mood disturbance, pelvic atro-
phy, lability, the risk of Alzheimer’s disease and improving 
quality of life (14, 21). Estrogen replacement therapy is also 
known to minimize the risk of cardiovascular diseases (21). 
Estrogen therapy (oral form) helps to reduce levels of low 
density lipoprotein (LDL) and increase levels of high density 
lipoprotein (HDL), thereby decreasing the risk of myocardi-
al infarction as well (22). Additionally, the use of estrogen 
therapy in patients of osteoporosis is also considered to be 
highly cost effective (21, 23).
On the negative side, studies have shown that oral estrogen 
therapy can lead to hepatic production of estrogen dependent 
proteins and bile changes that can cause complications like 
cholelithiasis, thrombophlebitis and pulmonary embolism. 
However, these complications can be prevented by admin-
istering transdermal estrogen (22). There is a known risk of 
abnormal uterine bleeding, endometrial hyperplasia and en-
dometrial carcinoma with estrogen therapy (21, 22, 24). Ad-
dition of progestin to the regimen can protect against these 
side effects (21, 24, 25). Additionally, there is a mild risk for 
breast cancer but this appears to be controversial and more 
related to the progestogen component of hormone replace-
ment therapy than estrogen. (14, 21). A review on the effect 
of progestin and progesterone in development of breast can-
cer however suggests that the increased risk is due to the use 
of synthetic progestin and continuous combined regimen and 
hence the risk can be avoided by using progesterone (and not 
synthetic progestin) in sequential or cyclic combined regi-
men (25). In this way the net effect is decrease in endometri-
al hyperplasia and cancer risk without the increase in the risk 
of breast cancer. Hypertension is also found to be associated 
with oral estrogen use, but the change in form, administra-
tion route and dose can help alleviate this side effect (21). In 
addition, there is some risk of thrombosis as well with oral 
estrogen but studies have shown that the risk only increased 
in those who have a positive family history for thrombosis 
or had a thrombotic event earlier in life. In such individuals, 
non-oral forms (transdermal patch/suppositories) are prefer-
able (21). A study demonstrates that  transdermal estrogen as 
compared to oral estrogen, does not decrease anti-thrombin 
III, low levels of which are considered to be associated with 
the development of thrombosis (26).
Conclusively, estrogen therapy has a major role in the 
management and prevention of osteoporosis in post-meno-
pausal women. Based on the data evaluated, it has efficiency 
in the reducing fractures in post-menopausal osteoporosis 
as well as osteoporosis in men (15, 20). Overall, the side ef-
fects attributed to the estrogen therapy can be reduced with 
changes in the dose regimens (low/ultra-low) and nature of 
preparation (oral/transdermal). The most detrimental being 
endometrial cancer, but studies have shown that it can be 
virtually eliminated with the addition of progesterone in the 
cyclic combined regimen (21, 24, 25). Majority of beneficial 
effects occur with long term use of estrogen therapy, howev-
er poor compliance has been reported as a major hindrance 
in achieving the desirable effects of this therapy (21, 27). 
The common reasons for non-compliance include lack of 
awareness about risks and benefits, misconceptions, advice 
of physician and phobia of side effects (27, 28). Additional 
studies should therefore be conducted to evaluate in detail 
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the causes of non -compliance with therapy so as to help 
determine strategies for improving compliance. The poten-
tial risk of estrogen replacement therapy must be weighed 
against the lifetime risks of developing cardiovascular dis-
eases (CVD), stroke, and bone fractures. The overall reduc-
tion in mortality and morbidity rates with estrogen use is 
generally viewed to be substantial and cost-effective. The 
benefit of quality of life improvement with estrogen ther-
apy should be taken into account in decision making and 
should be further evaluated via studies. Lastly, the health 
care professionals have an important role in shaping their 
patient’s attitudes and both the health care providers and pa-
tients must be fully informed and aware about the benefits 
and risks of estrogen therapy to make a better and beneficial 
decision.
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